文献速递其他结缔组织病血管炎

系统性硬化症并发间质性肺病相关肺动脉高压的预测因素与预后

Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于澳大利亚硬皮病队列研究1883例系统性硬化症患者,中位随访4.3年,164例(8.7%)发生肺动脉高压,其中43.9%合并间质性肺病。合并间质性肺病者生存更差;广泛间质性肺病患者使用血管扩张剂未改善生存,但症状、躯体功能和生活质量似有改善。

要点

  • 系统性硬化症患者中位随访4.3年,肺动脉高压累积发生率为8.7%(164/1883)。
  • 肺动脉高压诊断时43.9%合并间质性肺病,40.3%为广泛间质性肺病。
  • 合并间质性肺病与更差生存相关;广泛间质性肺病使用血管扩张剂未带来生存获益。

核心结论

  • 尽管使用血管扩张剂治疗,系统性硬化症相关肺动脉高压的生存仍较差,合并间质性肺病与更差生存相关。
  • 在广泛间质性肺病合并肺动脉高压患者中,诊断时起始血管扩张剂治疗未显示与生存改善相关,但似乎耐受良好,并可能改善症状、躯体功能和生活质量。

研究设计与样本

  • 连续纳入澳大利亚硬皮病队列研究中经右心导管确诊肺动脉高压的系统性硬化症患者。
  • 采用逻辑回归分析间质性肺病与肺动脉高压血流动力学参数及治疗方式的关联,采用Kaplan-Meier生存曲线估计生存率。

主要发现

  • 1883例系统性硬化症患者中,164例(8.7%)在中位随访4.3(1.7-7.9)年期间发生肺动脉高压。
  • 肺动脉高压诊断时43.9%合并间质性肺病,56.1%为第1组肺动脉高压;40.3%存在广泛间质性肺病。
  • 无论间质性肺病是否存在或严重程度如何,各肺动脉高压队列在诊断时接受血管扩张剂治疗的比例相似。
  • 广泛间质性肺病合并肺动脉高压患者中87.5%在诊断时起始血管扩张剂治疗,其耐受性或治疗终止情况与第1组肺动脉高压患者相比无差异。
  • 血管扩张剂治疗在广泛间质性肺病患者中未显示与生存获益相关,但其使用与症状缓解、躯体功能和生活质量改善相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to identify those SSc patients with concurrent pulmonary hypertension (PH) (SSc-PH patients) and interstitial lung disease (ILD) and determine their disease severity, therapeutic approach, and survival. METHODS: Consecutive SSc patients enrolled in the Australian Scleroderma Cohort Study (ASCS) who were diagnosed with pulmonary hypertension (via right-heart catherization) were included in the study. Logistic regression was used to determine the associations of ILD with PH hemodynamic parameters and therapeutic approach. Kaplan-Meier survival curves were used to estimate survival rates. RESULTS: Of 1883 SSc patients, 164 (8.7%) developed incident PH over a median follow-up of 4.3 (1.7-7.9) years. Of these, 43.9% had concurrent ILD at PH diagnosis (PH-ILD) and 56.1% had group 1 pulmonary arterial hypertension (PAH). Extensive ILD was present at PH diagnosis in 40.3%. Despite these distinct PH cohorts, a similar frequency of each PH cohort was treated with vasodilatory therapy at PH diagnosis, regardless of the presence or severity of ILD. The majority (87.5%) of those patients with extensive ILD and PH received upfront vasodilatory therapy at PH diagnosis, with no difference in its tolerability or therapy cessation being observed compared with the patients with group 1 PAH. Although vasodilator therapy was not associated with a survival advantage in those with extensive ILD, its use was associated with an amelioration of symptoms, and an improvement in physical function, and quality of life (QoL). CONCLUSION: Despite vasodilator therapy, survival in SSc-PH was found to be poor, with the presence of concurrent ILD being associated with worse survival. Although vasodilator therapy commenced at PH diagnosis was not shown to be associated with an improved survival in PH with extensive ILD, it appeared to be well tolerated and may improve symptoms, physical function, and QoL.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Morrisroe K, Hansen D, Stevens W, et al. Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 38471118. doi:10.1093/rheumatology/keae166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。